Skip to main content

Table 1 Patient characteristics

From: Prevention of Morbidity in Sickle Cell Disease (POMS2a)—overnight auto-adjusting continuous positive airway pressure compared with nocturnal oxygen therapy: a randomised crossover pilot study examining patient preference and safety in adults and children

 

Adults (n = 10)

Children (n = 11)

Male, n (%)

7 (70%)

6 (55%)

Receiving hydroxyurea, n (%)

5 (50%)

6 (55%)

Interviewed, n (%)

9 (90%)

7 (64%)

Nadir SpO2 < 2 standards below mean for age for people with RDI < 5 [26], n (%)

9 (90%)

9 (82%)

Mean SpO2 < 10th centile (96% [27]), n (%)

9 (90%)

9 (82%)

Nadir SpO2 < 10th centile (93.5% [27]), n (%)

10 (100%)

11 (100%)

Nadir SpO2 < 2.5th centile (85.2% [28]), n (%)

8 (80%)

9 (82%)

Nadir SpO2 < 2 standards below mean (86.8% [29]) , n (%)

9 (90%)

9 (82%)

Age (years), median (range)

30.2 (18–51.5)

12 (8.7–16.9)

Overnight oximetry over 2 nights, median (range)

 Mean SpO2 Median (range)

92.6 (87.7–97.3)

95.4 (85.0–97.7)

 Nadir SpO2 Median (range)

79 (65.5–87.4)

81.1 (73.7–90.7)

APAP adherence, median (range)

 Nights used

6 (3–7)

7 (1–7)

 Hours per night over 7 days

4.12 (0.55–6.77)

6.18 (0.75–9.19)

 Hours per night over nights used

5.67 (1.27–7.83)

6.18 (2.79–9.19)

  1. APAP auto-adjusting positive airway pressure, RDI Respiratory Disturbance Index, SpO2 oxygen saturation